Ribose (Furanose)

Ribose (Furanose)

SCHEMBL4391872

OC[C@H]1OC(O)[C@H](O)[C@@H]1O.c1ncc2[nH]cnc2n1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADA P00813 1/20 0.41
PNP P00491 1/20 0.37
ADK P55263 1/20 0.36
HIF1A Q16665 1/20 0.36
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCND1 P24385 1/20 0.34
MAPT P10636 2/20 0.34
CDA P32320 1/20 0.34
PYGL P06737 3/20 0.34
ATM Q13315 1/20 0.34
KDM4E B2RXH2 1/20 0.32
GMNN O75496 1/20 0.32
LMNA P02545 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL27484456 1.00 ADA (0.41) ADAPNPADKHIF1ACDK1
Ribose (Furanose) SCHEMBL5199714 1.00 ADA (0.41) ADAPNPADKHIF1ACDK1
Glucosamine SCHEMBL28890688 0.91 PYGL (0.38) ADAPNPADKHIF1ACDK1
Purine SCHEMBL11573661 0.82 P2RX3 (0.45) SMN1; SMN2
Purine SCHEMBL4378871 0.81 TREH (0.33) ADA
2-Aminopurine SCHEMBL28775710 0.79 ALDH1A1 (0.59) PNPADKHIF1APYGLKDM4E
Purine SCHEMBL6426435 0.79 ADORA2A (0.35) ADALMNA
Ribose (Furanose) SCHEMBL4391869 0.78 ADA (0.47) ADAPNPADKHIF1ACDK1
Purine SCHEMBL27770115 0.77 CYP3A4 (0.40) HIF1AKDM4ELMNA
Purine SCHEMBL28264029 0.77 ALDH1A1 (0.45) KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9611473-B2 Double-stranded nucleic acid compounds QUARK PHARMACEUTICALS, INC. (US) 2017-04-04 US disclosed
US-20150259676-A1 DOUBLE-STRANDED NUCLEIC ACID COMPOUNDS QUARK PHARMACEUTICALS, INC. (US) 2015-09-17 US disclosed
US-20090299049-A1 Bicyclic Compounds and Their Use REPLIZYME LIMITED (GB) 2009-12-03 US disclosed
EP-1984455-A2 BICYCLIC COMPOUNDS AND THEIR USE THE UNIVERSITY OF YORK (GB) 2008-10-29 EP disclosed
WO-2007091056-A2 BICYCLIC COMPOUNDS AND THEIR USE THE UNIVERSITY OF YORK (GB) 2007-08-16 WO disclosed
EP-0305643-B1 N-6 thienyl substituted adenosine derivatives as cardiac vasodilators WHITBY RESEARCH INC (US) 1994-01-05 EP disclosed
US-5043325-A N-6 substituted adenosine derivatives as cardiac vasodilators WHITBY RESEARCH, INC. (US) 1991-08-27 US disclosed
EP-0180614-B1 N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS Whitby Research Incorporated (US) 1990-03-07 EP disclosed
EP-0305643-A2 N-6 thienyl substituted adenosine derivatives as cardiac vasodilators Whitby Research Incorporated (US) 1989-03-08 EP disclosed
EP-0300144-A2 N-6 alkyl substituted adenosine derivatives as cardiac vasodilators Whitby Research Incorporated (US) 1989-01-25 EP disclosed
EP-0300145-A2 N-6 phenyl substituted adenosine derivatives as cardiac vasodilators Whitby Research Incorporated (US) 1989-01-25 EP disclosed
US-4728736-A HERPES VIRUS SOUTHERN RESEARCH INSTITUTE (US) 1988-03-01 US disclosed
EP-0180614-A1 N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS. NELSON RES & DEV (US) 1986-05-14 EP disclosed
WO-1985004882-A1 N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1985-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299049-A1 Bicyclic Compounds and Their Use ERCC4, PARP1, ERCC5 ADA 505/4885PNP 73/4885ADK 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.